ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2009
Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.The Cochrane database of systematic reviews · 2017Pooled it
- Response letter for the comment made on our article entitled "Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease", published online last May in the European Journal of Health Economics, doi: 10.1007/s10198-022-01471-9.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?PharmacoEconomics · 2015Review
- Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Article
- Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches.PharmacoEconomics · 2014Review
- Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta.Neuropsychiatric disease and treatment · 2013Review
- Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Autoimmune diseases · 2012Article
- When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Multiple sclerosis international · 2011Article
- Evolving expectations around early management of multiple sclerosis.Therapeutic advances in neurological disorders · 2010Article
- Assessing cost-effectiveness in the management of multiple sclerosis.ClinicoEconomics and outcomes research : CEOR · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapeutic options have modified the natural history and health care costs of multiple sclerosis (MS). An epidemiological 25 years-long model-based cost-utility analysis was performed following the Italian National Health Service (INHS) and societal perspectives to compare costs and quality-adjusted life years of treatment with Interferon beta-1b (IFNB-1b) from diagnosis of clinically isolated syndrome (CIS) versus treating at subsequent conversion to clinically definite MS (CDMS). Among patients treated (untreated) with IFNB-1b from CIS diagnosis, 40,420 (43,700) converted to CDMS after 25 years; the estimated cumulative probability of converting to CDMS during the first 3 years was 72.90% (84.94%) (P < 0.0001). Early treatment with IFNB-1b is highly cost-effective for the INHS (incremental cost-effectiveness ratio: Euros 2,574.94) and dominant from the societal viewpoint. Sensitivity analyses confirmed the base case findings. Early treatment with IFNB-1b delays conversion to CDMS in CIS patients and might be a "good value for money" health care programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.